Guardant Health Inc. (GH) is a Medical Specialities company listed on NASDAQ. In the last 30 days Quantisnow tracked 25 wire items for GH, including 11 press releases and news items, 5 insider trades and 5 SEC filings. The most recent was published Nov 12, 2026.
GH rankings
Financial highlights
Full financials- Revenue, TTM
- $1.28B
- Revenue growth
- +41.7%
- Net income, TTM
- -$485.07M
- Net margin
- -37.9%
- Free cash flow, TTM
- -$232.15M
- Cash
- $1.03B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks139+11%
2026-05-172026-11-08
Mix5990d
- Insider26(44%)
- Other21(36%)
- SEC Filings6(10%)
- Analyst3(5%)
- Earnings2(3%)
- Leadership1(2%)
Activity · 52 weeks268127 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- PRGuardant Health Prices $500 Million Convertible Senior Notes OfferingGuardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced the pricing of its offering of $500 million aggregate principal amount of 0% convertible senior notes due 2032 (the "notes") in a private offering (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The issuance and sale of the notes are scheduled to settle on November 16, 2026, subject to customary closing conditions. Guardant Health also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and inclu
- PRGuardant Health Announces Proposed $500.0 Million Offering of Convertible Senior Notes Due 2032Guardant Health, Inc. ("Guardant Health") (NASDAQ:GH), a leading precision oncology company, today announced its intention to offer $500.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in a private offering (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Guardant Health also intends to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $50.0 million aggregate principal amount of notes. The offe
- PRGuardant Health Introduces New Epigenomic Applications Providing Deeper Insights for Treatment Selection with Guardant360® LiquidPowered by InfinityAI, expanded capabilities bring together genomics and epigenomics to inform therapy selection in breast and lung cancers and identify additional treatment opportunities Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced new applications for Guardant360® Liquid designed to help oncologists understand how a patient’s cancer may respond to treatment in the absence of traditional biomarkers. The expanded capabilities include five key advances: Two novel epigenomic predictors identify patients that may benefit from selective estrogen receptor degraders (SERDs) in advanced breast cancer and immune checkpoint inhibitor (ICI) monotherap
- PRPRECISION Study Published in ESMO Open Highlights Utility of Guardant360® Liquid and Guardant Reveal® to Assess Recurrence Risk After Surgery for Colorectal Cancer MetastasesCombining pretreatment genomic profiling and postoperative molecular residual disease (MRD) testing identified patient groups with estimated two-year recurrence-free survival ranging from 78% to 9% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that ESMO Open has published results from PRECISION, a prospective multicenter observational study in Japan that enrolled 130 patients and evaluated complementary blood-based approaches for assessing recurrence risk in patients undergoing curative-intent surgery for colorectal cancer metastases. The study paired pretreatment comprehensive genomic profiling (CGP) using Guardant360® Liquid with postoperat
- PRGuardant Health to Participate in Upcoming Investor ConferencesGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UK Fireside chat on Wednesday, November 18 at 3:00 p.m. Greenwich Mean Time Piper Sandler 38th Annual Healthcare Conference in New York, NY Fireside chat on Tuesday, December 1 at 8:00 a.m. Eastern Time Interested parties may access live and archived webcasts of the sessions on the "Investors" section of the company website at: www.guardanthealth.com. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving e
- SECSEC Form 10-Q filed by Guardant Health Inc.10-Q - Guardant Health, Inc. (0001576280) (Filer)
- SECGuardant Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Guardant Health, Inc. (0001576280) (Filer)
- PRGuardant Health Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue GuidanceThird quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening Raises 2026 revenue guidance to $1.36 to $1.37 billion, representing growth of 38% to 40% Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today reported financial results for the quarter ended September 30, 2026. Third Quarter 2026 Financial Highlights For the three-month period ended September 30, 2026, as compared to the same period of 2025: Reported total revenue of $361.0 million, an increase of 36%, driven by: Oncology revenue of $231.3 million, an increase of 25%, and 117,000 oncology tests, an increase of 58% Biopharma & Data revenue of $59.0 millio
- 13D/GSEC Form SCHEDULE 13G filed by Guardant Health Inc.SCHEDULE 13G - Guardant Health, Inc. (0001576280) (Subject)
- PRTwinStrand Biosciences Announces USPTO Confirmation of Patentability of Core Duplex Sequencing PatentAll 23 claims of the ‘631 patent exclusively licensed to TwinStrand remain intact following unappealable decision on reexamination initiated by Guardant Health Decision follows second USPTO Patent Trial and Appeal Board ruling upholding all 30 challenged claims of the related ‘127 patent TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing technology, today announced that the U.S. Patent and Trademark Office (USPTO) has confirmed the patentability of all 23 claims of U.S. Patent No. 10,287,631 (the ‘631 patent), one of two foundational patents for Duplex Sequencing technology at issue in TwinStrand’s patent infringement litigation against Guardant Health, Inc. (NASDAQ:G
- SECGuardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Guardant Health, Inc. (0001576280) (Filer)
- PRKevin Sayer Joins Guardant Health Board of DirectorsGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. "We are excited to welcome Kevin Sayer to Guardant’s board," said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. "Kevin has played a pivotal role in advancing innovations that have transformed how people monitor and manage disease and has a strategic and operations record delivering significant growth. His expertise will be invaluable to Guardant as we continue to pion
- SECGuardant Health Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Guardant Health, Inc. (0001576280) (Filer)
- PRGuardant Health Wins 2026 Prix Galien USA Award for Best Medical Technology for Shield Blood TestShield blood test for colorectal cancer (CRC) recognized for impact in increasing screening participation for CRC and closing today’s screening gaps Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, announced it received the 2026 Prix Galien USA Award for Best Medical Technology for Shield™, the leading blood test for colorectal cancer (CRC) detection and first to receive FDA approval for primary CRC screening, for its achievements in expanding patient choice and increasing screening participation for CRC. Established in 2007, the Prix Galien USA Awards recognize the leading scientific advances in life sciences that contribute to improving human health worldwide
- PRGuardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for PennsylvaniansTwo million more screening-eligible Pennsylvanians will now have access to the Shield blood test for colorectal cancer (CRC) with no cost-sharingGuardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, applauded the enactment of a new law (HB 1123) in Pennsylvania aligning insurance coverage for colorectal cancer screening to reflect the latest American Cancer Society (ACS) and National Comprehensive Cancer Center (NCCN) guidelines, ensuring no cost-sharing for about 2 million Pennsylvanians of screening-eligible age.1The landmark legislation marks a historic moment for states proactively aligning state policy with the latest research and innovations for colorectal cancer scr
- ANALYSTRoth Capital initiated coverage on Guardant Health with a new price targetRoth Capital initiated coverage of Guardant Health with a rating of Buy and set a new price target of $200.00
- INSIDERSEC Form 4 filed by Guardant Health Inc.4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRGuardant Health Highlights Broad Liquid Biopsy Research Portfolio at ESMO Congress 2026Research reinforces the significance of genomic and epigenomic profiling approaches to characterize tumor types, identify biomarkers, and support risk stratification Presentations reflect Guardant’s strong biopharma and academic collaborations, along with public-private partnerships in Europe Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced that the company and its research collaborators will present 25 abstracts—including five rapid oral presentations—demonstrating advances in methylation-based circulating tumor DNA (ctDNA) monitoring and liquid biopsy technology across lung, colorectal, and gastric cancers at the European Society for Medical
- INSIDERSEC Form 4 filed by Guardant Health Inc.4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Tariq Musa sold $19,242 worth of shares (116 units at $165.88) as part of a pre-agreed trading plan (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- INSIDERDirector Azar Alex M Ii sold $11,032 worth of shares (69 units at $159.89) as part of a pre-agreed trading plan (SEC Form 4)4 - Guardant Health, Inc. (0001576280) (Issuer)
- PRTwinStrand Biosciences Announces Second U.S. Patent Trial and Appeal Board Decision Upholding All Claims of TwinStrand’s ‘127 PatentFollowing Federal Circuit remand, the PTAB again rules in favor of the University of Washington and TwinStrand on all 30 claims of the ’127 patent challenged by Guardant Health TwinStrand Biosciences (TwinStrand), the pioneer in Duplex Sequencing® technology, today announced that the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) has again rejected Guardant Health, Inc.’s (NASDAQ:GH) challenge to a core patent underlying Duplex Sequencing. In an Oct. 14, 2026, Final Written Decision on remand from the U.S. Court of Appeals for the Federal Circuit, the PTAB ruled in favor of the University of Washington (UW), determining that Guardant Health failed to establish the
- PRGuardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based TestsModeling study provides strong data on real-world follow-up colonoscopy adherence and CRC deaths averted for blood-based testing vs stool-based testing New data demonstrates notable screening adherence rate of 99% in medically-underserved populations for Shield blood-based colorectal cancer (CRC) screening test Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing in increasing overall colorectal cancer (CRC) screening and follow-up colonoscopy adherence at the American College of Gastroenterology (ACG) 2026 Annual Meeting in Nashville, Ten
- SECSEC Form 144 filed by Guardant Health Inc.144 - Guardant Health, Inc. (0001576280) (Subject)
- INSIDERSEC Form 4 filed by Guardant Health Inc.4 - Guardant Health, Inc. (0001576280) (Issuer)
GH FAQ
11 questionsWhat does Guardant Health Inc. do?
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing tests from its LUNAR program for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; LUNAR-2 test for the early detection of cancer in asymptomatic...What is the latest news on GH?
In the last 30 days Quantisnow tracked 25 wire items for GH: 11 press releases and news items, 5 insider trades, 5 SEC filings and 1 analyst rating. The most recent was published on November 12, 2026.What is GH revenue?
Guardant Health Inc. (GH) reported $1.28B of revenue for the twelve months ended Sep 30, 2026. That is up 41.7% from the year before. Revenue for fiscal 2025 was $982.02M.Is GH profitable?
No. Guardant Health Inc. reported a net loss of $485.07M for the twelve months ended Sep 30, 2026.How much cash and debt does GH have?
Guardant Health Inc. reported $1.03B in cash and cash equivalents and $1.50B of debt on its most recent balance sheet in SEC filings.Where does GH stock trade?
Guardant Health Inc. (GH) is listed on NASDAQ.What sector and industry is GH in?
Guardant Health Inc. operates in the Health Care sector, Medical Specialities industry.When did Guardant Health Inc. go public?
Guardant Health Inc. (GH) completed its IPO in 2018.What are analysts saying about GH?
Across the last 8 analyst actions on Guardant Health Inc., there was 1 upgrade and 0 downgrades. The most recent action was from Roth Capital: Buy with a $200.00 price target on 2026-10-23. Recent price targets range from $150.00 to $225.00.What companies are similar to GH?
Notable peers in the same industry include ELV (Elevance Health Inc.), HUM (Humana Inc.), NTRA (Natera Inc.), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated). Compare GH side-by-side with any of them on Quantisnow.How can I track GH on Quantisnow?
Quantisnow aggregates Guardant Health Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GH to receive live email and push alerts on every new disclosure.